Altered binding site selection of p53 transcription cassettes by hepatitis B virus X protein

Molecular and Cellular Biology

Volumn 33, Issue 3, 2013, Pages 485-497

  Chan, Cheryl ^a,c   Wang, Yu ^c   Chow, Pierce K H ^d,e   Chung, Alexander Y F ^e   Ooi, London L P J ^c,e   Lee, Caroline G ^a,b,c,d  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c DIVISION OF MEDICAL ONCOLOGY   (Singapore)

^d DUKE NUS MEDICAL SCHOOL   (Singapore)

^e SINGAPORE GENERAL HOSPITAL   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS B VIRUS X PROTEIN; PROTEIN P53;

ACETYLATION; APOPTOSIS; ARTICLE; BINDING SITE; CANCER CELL CULTURE; CELL STRAIN HEPG2; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; DOWN REGULATION; GENE CASSETTE; GENE EXPRESSION PROFILING; GENETIC ASSOCIATION; HEPATITIS B VIRUS; HUMAN; HUMAN CELL; IN VITRO STUDY; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN MOTIF; PROTEIN PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSCRIPTION REGULATION; ULTRAVIOLET IRRADIATION; UPREGULATION; WILD TYPE;

APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; BINDING SITES; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; DNA; GENE EXPRESSION REGULATION, NEOPLASTIC; HEPATITIS B; HEPATITIS B VIRUS; HOST-PATHOGEN INTERACTIONS; HUMANS; LIVER NEOPLASMS; PHOSPHORYLATION; PROTEIN BINDING; REGULATORY SEQUENCES, NUCLEIC ACID; TRANS-ACTIVATORS; TRANSCRIPTIONAL ACTIVATION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84873022472     PISSN: 02707306     EISSN: 10985549     Source Type: Journal    
DOI: 10.1128/MCB.01189-12     Document Type: Article

References (49)

1. Vogelstein B, Lane D, Levine AJ. 2000. Surfing the p53 network. Nature 408:307-310.
2. Bargonetti J, Friedman PN, Kern SE, Vogelstein B, Prives C. 1991. Wild-type but not mutant p53 immunopurified proteins bind to sequences adjacent to the SV40 origin of replication. Cell 65:1083-1091.
3. Kern SE, Kinzler KW, Bruskin A, Jarosz D, Friedman P, Prives C, Vogelstein B. 1991. Identification of p53 as a sequence-specific DNA-binding protein. Science 252:1708-1711.
4. Appella E, Anderson CW. 2001. Post-translational modifications and activation of p53 by genotoxic stresses. Eur. J. Biochem. 268:2764-2772.
5. Shieh SY, Ikeda M, Taya Y, Prives C. 1997. DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2. Cell 91:325-334.
6. Unger T, Juven-Gershon T, Moallem E, Berger M, Vogt Sionov R, Lozano G, Oren M, Haupt Y. 1999. Critical role for Ser20 of human p53 in the negative regulation of p53 by Mdm2. EMBO J. 18:1805-1814.
7. Chuikov S, Kurash JK, Wilson JR, Xiao B, Justin N, Ivanov GS, McKinney K, Tempst P, Prives C, Gamblin SJ, Barlev NA, Reinberg D. 2004. Regulation of p53 activity through lysine methylation. Nature 432: 353-360.
8. Gu W, Roeder RG. 1997. Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain. Cell 90:595-606.
9. Luo J, Li M, Tang Y, Laszkowska M, Roeder RG, Gu W. 2004. Acety-lation of p53 augments its site-specific DNA binding both in vitro and in vivo. Proc. Natl. Acad. Sci. U. S. A. 101:2259-2264.
10. Oda K, Arakawa H, Tanaka T, Matsuda K, Tanikawa C, Mori T, Nishimori H, Tamai K, Tokino T, Nakamura Y, Taya Y. 2000. p53AIP1, a potential mediator of p53-dependent apoptosis, and its regulation by Ser-46-phosphorylated p53. Cell 102:849-862.
11. Querido E, Marcellus RC, Lai A, Charbonneau R, Teodoro JG, Ketner G, Branton PE. 1997. Regulation of p53 levels by the E1B 55-kilodalton protein and E4orf6 in adenovirus-infected cells. J. Virol. 71:3788-3798.
12. Saha A, Murakami M, Kumar P, Bajaj B, Sims K, Robertson ES. 2009. Epstein-Barr virus nuclear antigen 3C augments Mdm2-mediated p53 ubiquitination and degradation by deubiquitinating Mdm2. J. Virol. 83: 4652-4669.
13. Scheffner M, Huibregtse JM, Vierstra RD, Howley PM. 1993. The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. Cell 75:495-505.
14. Scheffner M, Werness BA, Huibregtse JM, Levine AJ, Howley PM. 1990. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 63:1129-1136.
15. Steegenga WT, Riteco N, Jochemsen AG, Fallaux FJ, Bos JL. 1998. The large E1B protein together with the E4orf6 protein target p53 for active degradation in adenovirus infected cells. Oncogene 16:349-357.
16. Lechner MS, Laimins LA. 1994. Inhibition of p53 DNA binding by human papillomavirus E6 proteins. J. Virol. 68:4262-4273.
17. Lechner MS, Mack DH, Finicle AB, Crook T, Vousden KH, Laimins LA. 1992. Human papillomavirus E6 proteins bind p53 in vivo and abrogate p53-mediated repression of transcription. EMBO J. 11:3045-3052.
18. Yi F, Saha A, Murakami M, Kumar P, Knight JS, Cai Q, Choudhuri T, Robertson ES. 2009. Epstein-Barr virus nuclear antigen 3C targets p53 and modulates its transcriptional and apoptotic activities. Virology 388: 236-247.
19. Zhao LY, Santiago A, Liu J, Liao D. 2007. Repression of p53-mediated transcription by adenovirus E1B 55-kDa does not require corepressor mSin3A and histone deacetylases. J. Biol. Chem. 282:7001-7010.
20. Kim CM, Koike K, Saito I, Miyamura T, Jay G. 1991. HBx gene of hepatitis B virus induces liver cancer in transgenic mice. Nature 351:317-320.
21. Koike K, Moriya K, Iino S, Yotsuyanagi H, Endo Y, Miyamura T, Kurokawa K. 1994. High-level expression of hepatitis B virus HBx gene and hepatocarcinogenesis in transgenic mice. Hepatology 19:810-819.
22. Madden CR, Finegold MJ, Slagle BL. 2001. Hepatitis B virus X protein acts as a tumor promoter in development of diethylnitrosamine-induced preneoplastic lesions. J. Virol. 75:3851-3858.
23. Seifer M, Hohne M, Schaefer S, Gerlich WH. 1991. In vitro tumorige-nicity of hepatitis B virus DNA and HBx protein. J. Hepatol 13(Suppl. 4):S61-S65.
24. Doria M, Klein N, Lucito R, Schneider RJ. 1995. The hepatitis B virus HBx protein is a dual specificity cytoplasmic activator of Ras and nuclear activator of transcription factors. EMBO J. 14:4747-4757.
25. Henkler F, Hoare J, Waseem N, Goldin RD, McGarvey MJ, Koshy R, King IA. 2001. Intracellular localization of the hepatitis B virus HBx protein. J. Gen. Virol. 82:871-882.
26. Hoare J, Henkler F, Dowling JJ, Errington W, Goldin RD, Fish D, McGarvey MJ. 2001. Subcellular localisation of the X protein in HBV infected hepatocytes. J. Med. Virol. 64:419-426.
27. Rahmani Z, Huh KW, Lasher R, Siddiqui A. 2000. Hepatitis B virus X protein colocalizes to mitochondria with a human voltage-dependent an-ion channel, HVDAC3, and alters its transmembrane potential. J. Virol. 74:2840-2846.
28. Takada S, Shirakata Y, Kaneniwa N, Koike K. 1999. Association of hepatitis B virus X protein with mitochondria causes mitochondrial aggregation at the nuclear periphery, leading to cell death. Oncogene 18: 6965-6973.
29. Feitelson MA, Zhu M, Duan LX, London WT. 1993. Hepatitis B x antigen and p53 are associated in vitro and in liver tissues from patients with primary hepatocellular carcinoma. Oncogene 8:1109-1117.
30. Truant R, Antunovic J, Greenblatt J, Prives C, Cromlish JA. 1995. Direct interaction of the hepatitis B virus HBx protein with p53 leads to inhibition by HBx of p53 response element-directed transactivation. J. Virol. 69:1851-1859.
31. Wang XW, Forrester K, Yeh H, Feitelson MA, Gu JR, Harris CC. 1994. Hepatitis B virus X protein inhibits p53 sequence-specific DNA binding, transcriptional activity, and association with transcription factor ERCC3. Proc. Natl. Acad. Sci. U. S. A. 91:2230-2234.
32. Maguire HF, Hoeffler JP, Siddiqui A. 1991. HBV X protein alters the DNA binding specificity of CREB and ATF-2 by protein-protein interactions. Science 252:842-844.
33. Williams JS, Andrisani OM. 1995. The hepatitis B virus X protein targets the basic region-leucine zipper domain of CREB. Proc. Natl. Acad. Sci. U. S. A. 92:3819-3823.
34. Choi BH, Choi M, Jeon HY, Rho HM. 2001. Hepatitis B viral X protein overcomes inhibition of E2F1 activity by pRb on the human Rb gene promoter. DNA Cell Biol. 20:75-80.
35. Sung WK, Lu Y, Lee CW, Zhang D, Ronaghi M, Lee CG. 2009. Deregulated direct targets of the hepatitis B virus (HBV) protein, HBx, identified through chromatin immunoprecipitation and expression mi-croarray profiling. J. Biol. Chem. 284:21941-21954.
36. Cougot D, Wu Y, Cairo S, Caramel J, Renard CA, Levy L, Buendia MA, Neuveut C. 2007. The hepatitis B virus X protein functionally interacts with CREB-binding protein/p300 in the regulation of CREB-mediated transcription. J. Biol. Chem. 282:4277-4287.
37. Lin Y, Nomura T, Yamashita T, Dorjsuren D, Tang H, Murakami S. 1997. The transactivation and p53-interacting functions of hepatitis B virusXprotein are mutually interfering but distinct. Cancer Res. 57:5137-5142.
38. Ogden SK, Lee KC, Barton MC. 2000. Hepatitis B viral transactivator HBx alleviates p53-mediated repression of alpha-fetoprotein gene expression. J. Biol. Chem. 275:27806-27814.
39. Chung TW, Lee YC, Ko JH, Kim CH. 2003. Hepatitis B virus X protein modulates the expression of PTEN by inhibiting the function of p53, a transcriptional activator in liver cells. Cancer Res. 63:3453-3458.
40. Lee AT, Ren J, Wong ET, Ban KH, Lee LA, Lee CG. 2005. The hepatitis B virus X protein sensitizes HepG2 cells to UV light-induced DNA damage. J. Biol. Chem. 280:33525-33535.
41. Hoh J, Jin S, Parrado T, Edington J, Levine AJ, Ott J. 2002. The p53MH algorithm and its application in detecting p53-responsive genes. Proc. Natl. Acad. Sci. U. S. A. 99:8467-8472.
42. Wei CL, Wu Q, Vega VB, Chiu KP, Ng P, Zhang T, Shahab A, Yong HC, Fu Y, Weng Z, Liu J, Zhao XD, Chew JL, Lee YL, Kuznetsov VA, Sung WK, Miller LD, Lim B, Liu ET, Yu Q, Ng HH, Ruan Y. 2006. A global map of p53 transcription-factor binding sites in the human genome. Cell 124:207-219.
43. Ryoo HD, Gorenc T, Steller H. 2004. Apoptotic cells can induce compensatory cell proliferation through the JNK and the Wingless signaling pathways. Dev. Cell 7:491-501.
44. Harrod R, Nacsa J, Van Lint C, Hansen J, Karpova T, McNally J, Franchini G. 2003. Human immunodeficiency virus type-1 Tat/co-activator acetyltransferase interactions inhibit p53Lys-320 acetylation and p53-responsive transcription. J. Biol. Chem. 278:12310-12318.
45. Liu Y, Colosimo AL, Yang XJ, Liao D. 2000. Adenovirus E1B 55-kilodalton oncoprotein inhibits p53 acetylation by PCAF. Mol. Cell. Biol. 20:5540-5553.
46. Olsson A, Manzl C, Strasser A, Villunger A. 2007. How important are post-translational modifications in p53 for selectivity in target-gene transcription and tumour suppression? Cell Death Differ. 14:1561-1575.
47. Knights CD, Catania J, Di Giovanni S, Muratoglu S, Perez R, Swartz-Beck A, Quong AA, Zhang X, Beerman T, Pestell RG, Avantaggiati ML. 2006. Distinct p53 acetylation cassettes differentially influence gene-expression patterns and cell fate. J. Cell Biol. 173:533-544.
48. Chao C, Wu Z, Mazur SJ, Borges H, Rossi M, Lin T, Wang JY, Anderson CW, Appella E, Xu Y. 2006. Acetylation of mouse p53 at lysine 317 negatively regulates p53 apoptotic activities after DNA damage. Mol. Cell. Biol. 26:6859-6869.
49. Terui T, Murakami K, Takimoto R, Takahashi M, Takada K, Murakami T, Minami S, Matsunaga T, Takayama T, Kato J, Niitsu Y. 2003. Induction of PIG3 and NOXA through acetylation of p53 at 320 and 373 lysine residuesasamechanism for apoptotic cell deathby histone deacety-lase inhibitors. Cancer Res. 63:8948-8954.